Implementing an Ebola Vaccine Study — Sierra Leone

Widdowson, Marc‐Alain; Schrag, Stephanie J.; Carter, Rosalind J.; Carr, Wendy; Legardy-Williams, Jennifer; Gibson, Laura; Lisk, Durodami Radcliffe; Jalloh, Mohamed I; Bash-Taqi, Donald; Kargbo, S A S; Idriss, Ayesha; Deen, Gibrilla F.; Russell, James; Mcdonald, W. M.; Albert, Alison P.; Basket, Michelle; Callis, Amy; Carter, Victoria M; Ogunsanya, Kelli R Clifton; Gee, Julianne; Pinner, Robert W.; Mahon, Barbara E.; Goldstein, Susan T.; Seward, Jane F.; Samai, Mohamed; Schuchat, Anne

doi:10.15585/mmwr.su6503a14

Cited by 65 publications

(57 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some areas of research include less common modes of virus transmission, virus persistence, virus reservoirs, clinical sequelae and disease spectrum, development of faster reliable laboratory tests and genetic analysis methods for virus characterization, improved information technology systems for use in the field, and effectiveness and safety of Ebola therapeutic drugs and vaccines, such as the Sierra Leone Trial to Introduce a Vaccine against Ebola (21).…”

Section: Resultsmentioning

confidence: 99%

Overview, Control Strategies, and Lessons Learned in the CDC Response to the 2014–2016 Ebola Epidemic

Bell

Damon²,

Jernigan³

et al. 2016

MMWR Suppl.

177

168

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Overview, Control Strategies, and Lessons Learned in the CDC Response to the 2014–2016 Ebola Epidemic

Bell

Damon²,

Jernigan³

et al. 2016

MMWR Suppl.

177

168

View full text Add to dashboard Cite

show abstract

“…In addition, all participants of the study will be followed for 6 months after vaccination to monitor for occurrence of serious adverse effects and EVD [99]. As of April 2016, no cases of EBOV infection nor vaccine-related serious adverse events (as defined by death, life-threatening illness, hospitalization or prolongation of hospitalization, or permanent disability), were reported from the participants in the study [100]. …”

Section: Efficacy Of Ebov Vaccine Candidates In Phase 2/3 Clinicalmentioning

confidence: 99%

From bench to almost bedside: the long road to a licensed Ebola virus vaccine

Wong

Mendoza

Plummer

et al. 2017

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction The Ebola virus (EBOV) disease epidemic during 2014-16 in West Africa has accelerated the clinical development of several vaccine candidates that have demonstrated efficacy in the gold standard nonhuman primate (NHP) model, namely cynomolgus macaques. Areas covered This review discusses the pre-clinical research and if available, clinical evaluation of the currently available EBOV vaccine candidates, while emphasizing the translatability of pre-clinical data generated in the NHP model to clinical data in humans. Expert opinion Despite the existence of many successful EBOV vaccine candidates in the pre-clinical stages, only two platforms became the focus of Phase 2/3 efficacy trials in Liberia, Sierra Leone, and Guinea near the peak of the epidemic: the Vesicular stomatitis virus (VSV)-vectored vaccine and the chimpanzee adenovirus type 3 (ChAd3)-vectored vaccine. The results of three distinct clinical trials involving these candidates may soon pave the way for a licensed, safe and efficacious EBOV vaccine to help combat future epidemics.

show abstract

“…With MoHS and other partners, CDC participated in several studies during the Ebola response, including the Sierra Leone Trial to Introduce a Vaccine against Ebola (27). In addition, with MoHS and WHO, CDC initiated the Virus Persistence Study to assess the length of Ebola virus shedding in the semen of survivors (25).…”

Section: Sierra Leonementioning

confidence: 99%